PON1 M/L55 mutation protects high-risk patients against coronary artery disease

International Journal of Cardiology

Volumn 94, Issue 1, 2004, Pages 73-77

  Oliveira, Simone A ^a   Mansur, Antonio P ^b   Ribeiro, Cristina C ^a   Ramires, José Antonio F ^b   Annichino Bizzacchi, Joyce M ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Coronary artery disease; Paraoxonase; Polymorphism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 92; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SMOKING;

ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; BRAZIL; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK FACTORS; SMOKING;

EID: 1542316808     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.05.011     Document Type: Article

References (27)

1. Mackness M.I., Arrol S., Abbott C.A., Durrington P.N. Is paraoxonase related to atherosclerosis? Chem. Biol. Interactions. 87:1993;161-171.
2. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 32:1986;671-673.
3. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S.et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394:1998;284-287.
4. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet. 3:1993;73-76.
5. Ruiz J., Blanche H., James R.W., Garin M.C., Vaise C., Charpentier G. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 346:1995;869-872.
6. Serrato M., Marian A.J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J. Clin. Invest. 96:1995;3005-3008.
7. Sanghera D.K., Saha N., Aston C.E., Kamboh M.I. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;1067-1073.
8. Odawara M., Tachi Y., Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;2257-2260.
9. Zama T., Murata M., Matsubara Y., Kawano K., Aoki N., Yoshino H.et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler. Thromb. Vasc. Biol. 17:1997;3565-3569.
10. Herrmann S.M., Blanc H., Poirier O., Arveiler D., Luc G., Evans A.et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis. 126:1996;299-303.
11. Antikainen M., Murtomaki S., Syvanne M., Pahlman R., Tahvanainen E., Jauhiainen M.et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J. Clin. Invest. 98:1996;883-885.
12. Suehiro T., Nakauchi Y., Yamamoto M., Arii K., Itoh H., Hamashige N.et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int. J. Cardiol. 57:1996;69-73.
13. Garin M.C., James R.W., Dussoix P., Blanche H., Passa P., Froguel P.et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99:1997;62-66.
14. Sanghera D.K., Aston C.E., Saha N., Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62:1998;36-44.
15. Mochizuki H., Scherer S.W., Xi T., Nickle D.C., Majer M., Huizenga J.J. et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene. 213:1998;149-157.
16. Boright A.P., Connelly P.W., Brunt J.H., Scherer S.W., Tsui L.C., Hegele R.A. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis. 139:1998;131-136.
17. Hegele R.A., Connelly P.W., Scherer S.W., Hanley A.J., Harris S.B., Tsui L.C.et al. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 82:1997;3373-3377.
18. Imai Y., Morita H., Kurihara H., Sugiyama T., Kato N., Ebihara A.et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis. 149:2000;435-442.
19. Saiki R.K., Gelfand D.H., Stoffel S., Scharf S.J., Higuchi R., Horn G.T.et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 239:1988;487-491.
20. Voetsch B., Benke K.S., Damasceno B.P., Siqueira L.H., Loscalzo J. Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke. 33:2002;1459-1464.
21. Rice G.I., Ossei-Gerning N., Stickland M.H., Grant P.J. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron. Artery Dis. 8:1997;677-682.
22. Ombres D., Pannitteri G., Montali A., Candeloro A., Seccareccia F., Campagna F.et al. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler. Thromb. Vasc. Biol. 18:1998;1611-1616.
23. Mackness B., Davies G.K., Turkie W., Lee E., Roberts D.H., Hill E.et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21:2001;1451-1457.
24. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7:1996;69-76.
25. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101:1998;1581-1590.
26. Laan M., Paabo S. Demographic history and linkage disequilibrium in human populations. Nat. Genet. 17:1997;435-438.
27. McKeigue P.M. Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations. Am. J. Hum. Genet. 60:1997;188-196.